NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

TuHURA Biosciences, Inc. (HURA) Stock Analysis

TuHURA Biosciences, Inc. (HURA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

HURA

$2.14

+$0.04 (+1.90%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HURA with… →

HURA Key Statistics

As of Sep 4, 2026
Trading
Open
$2.09
Previous Close
$2.10
Day's Range
2.06–2.16
52-Week Range
0.41–3.43
Volume
367.80K
Valuation
Market Cap
$136.37M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.55
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$30.05M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
63.73M
1-Year Return
−15.42%
Dividend and dates
Earnings Date
November 13, 2026estimated
Avg Volume
414.04K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HURA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+182.69%
2025−81.49%
2024−31.26%
2023−97.53%
2022−72.98%
2021−60.16%
2020+85.51%
2019−79.82%
2018−68.62%
2017−65.82%
2016 (partial year)−51.68%

As of September 4, 2026.

HURA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$30.05M—
2024$0.00−$21.68M—
2023$0.00−$29.32M—
2022$0.00−$9.37M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$27.29M−$30.05M—
2024$0.00—−$17.15M−$21.68M—
2023$0.00—−$13.17M−$29.32M—
2022$0.00—−$9.72M−$9.37M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HURA Valuation vs Biotechnology Median

Median of 656 stocks
MetricHURABiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values TuHURA Biosciences, Inc. (HURA) at $136.37M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 22.

The most recent close on file for HURA is $2.14, dated September 4, 2026. That is +$0.04 (+1.90%) against the previous close. Over the past 52 weeks the price has ranged from $0.41 to $3.43. The latest close sits 421.95% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $30.05M. Profit margin runs at 0%. Trailing earnings per share are −0.55.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year price return is −15.42%. Across 10 years the annualized return works out at −66.71%. Annualized volatility over the trailing 10 years is 128.5%.

Growth & Income

No dividend is on file for HURA.

Across the complete calendar years on file, 2020 returned +85.51% and 2023 returned −97.53%. Of the 9 complete calendar years on file, 1 finished higher. 2026 is still running; the price is +182.69% year to date.

Peer Comparison

TuHURA Biosciences, Inc. (HURA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TuHURA Biosciences, Inc. HURA $136.37M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. TuHURA Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Visit website →